NOTCH2 and pancreatic adenocarcinoma: Tarextumab has recently tested in a phase II clinical trial for the treatment of pancreatic adenocarcinoma and pulmonary small cell carcinoma, which exhibit dysregulated NOTCH2 and/or NOTCH3 activity in tumor cells [48].